Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Consolidation in Stage I/II Hodgkin's Lymphoma
NCT02298283Phase 2Completed
- Sponsor
- LYSARC
- Start
- Apr 2015
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by LYSARC. Started Apr 2015; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02298283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02298283.